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BuccalConstitutive androstane receptor (CAR) encoded by the nuclear receptor subfamily 1, group I, member 3 (NR1I3)
gene regulates the elimination of bilirubin through activating the components of the bilirubin clearance pathway.
Hence, NR1I3 genetic variants may affect bilirubin metabolism and result in neonatal hyperbilirubinemia. Thus
far, research which investigates the association between NR1I3 variants and neonatal hyperbilirubinemia has
not been undertaken in any population. The present study aimed to evaluate the inﬂuence of MPJ6_1I3008
(rs10157822), IVS8+116TNG (rs4073054) and 540ANG (rs2307424) on neonatal hyperbilirubinemia develop-
ment in the Malay population. Buccal swabs were collected from 232 hyperbilirubinemia and 277 control term
newborns with gestational age ≥37 weeks and birth weight ≥2500 g. The NR1I3 variants were genotyped by
using high resolution melting (HRM) assays and veriﬁed by DNA sequencing. Gender, mode of delivery and
birthweight did not differ between hyperbilirubinemia and control groups. The genotypic and allelic frequencies
ofMPJ6_1I3008, IVS8+116TNG and 540ANGwere not signiﬁcantly different between the groups. However, strat-
iﬁcation by gender revealed a signiﬁcant inverse association between homozygous variant genotype of
MPJ6_1I3008 and risk of neonatal hyperbilirubinemia in the females (OR, 0.44; 95% CI, 0.20–0.95; p = 0.034).
This study demonstrates that thehomozygous variant genotype ofMPJ6_1I3008was associatedwith a signiﬁcant
reduced risk of neonatal hyperbilirubinemia in the females.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neonatal hyperbilirubinemia or jaundice is a benign and common
clinicalmanifestation of thenewborns (AmericanAcademyof Pediatrics
Subcommittee on Hyperbilirubinemia, 2004; Bhutani et al., 2010). The
prevalence is 60% in term and 80% in preterm newborns (Rennie et al.,
2010; The Lancet, 2010). Hyperbilirubinemia occurs due to an elevated
production of bilirubin from senescent erythrocytes or reduced elimina-
tion of bilirubin from the body (Kaplan et al., 2002). Although neonatal
hyperbilirubinemia is a natural phenomenon, an elevated serum biliru-
bin level has the potential to produce permanent brain damagetor; NR1I3, nuclear receptor
lting; UGT1A1, uridine diphos-
osyltransferase phenobarbital-
NP, single nucleotide polymor-
perature.
s, School of Medical Sciences,
. This is an open access article under(kernicterus) or even death if it is not recognized and treated properly
(Johnson et al., 2009).
Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is the
key enzyme which conjugates bilirubin with glucuronic acid for the sub-
sequent bilirubin elimination (Bosma et al., 1994). The promoter region
of the UGT1A1 gene contains glucuronosyltransferase phenobarbital-
responsive enhancer module (gtPBREM) that is regulated by constitutive
androstane receptor (CAR) (Sugatani et al., 2001). In response to pheno-
barbital induction, CAR binds to the gtPBREM resulting in an elevated
UGT1A1 transcription thereby enhancing the metabolism of bilirubin
(Sugatani et al., 2001). Besides, other transcription factors which also
regulate the transcription of UGT1A1 by binding to the gtPBREM include
the pregnane X receptor (Sugatani et al., 2005), aryl hydrocarbon recep-
tor (Yueh et al., 2003), nuclear erythroid-related factor 2 (Yueh and
Tukey, 2007), peroxisome proliferator-activated receptor α (Senekeo-
Effenberger et al., 2007) and glucocorticoid receptor (Sugatani et al.,
2005).
CAR is an orphan nuclear receptor encoded by the nuclear
receptor subfamily 1, group I, member 3 (NR1I3) gene (Baes et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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functions in transactivating hepatic xenobiotic-metabolizing enzymes
including cytochrome P450s (Chen et al., 2003; Park et al., 2012) and
transferases [glutathione S-transferase (GST), sulfotransferases and
UGT1A1] (Sugatani et al., 2001). Genetic variants in the NR1I3 gene
are associated with neonatal hyperbilirubinemia because CARmonitors
the elimination of bilirubin through activating components [solute car-
rier organic anion transporter (SLCO1B1), GSTA1, GSTA2, UGT1A1 and
multidrug resistance-associated protein 2 (MRP2)] in the bilirubin
clearance pathway (Huang et al., 2003). During hyperbilirubinemia,
CAR activates these components to result in a greater bilirubin
clearance (Huang et al., 2003). Hence, it is possible that the NR1I3
variants may affect bilirubin metabolism and thus result in neonatal
hyperbilirubinemia.
Thus far, research which investigates the association between vari-
ants in the NR1I3 gene and neonatal hyperbilirubinemia occurrence
has not been undertaken in any population. Based on the NR1I3 variant
screening results (Ikeda et al., 2003; Chew et al., 2013), the present
study aimed to determine the inﬂuence of common variants
MPJ6_1I3008 (rs10157822), IVS8+116TNG (rs4073054) and 540ANG
(rs2307424) on the development of neonatal hyperbilirubinemia in
the Malay population.
2. Materials and methods
2.1. Study subjects
This was a comparative cross-sectional study involving subjects
admitted to and/or born in Hospital Universiti Sains Malaysia (HUSM),
Kelantan, Malaysia from April 2013 to October 2014. Ethical approval
of the study was obtained from Human Research Ethics Committee
of Universiti Sains Malaysia (No. USMKK/PPP/JEPeM[263.3.(12)]).
Informed consent was obtained from the parents before recruiting a
total of 509 subjects which comprised 232 hyperbilirubinemia and
277 non-hyperbilirubinemia newborns. Subjects from both groups
were Malay term newborns with gestational age ≥37 weeks and birth
weight ≥2500 g.
Newborns who developed total serum bilirubin (TSB) levels
≥250 μmol/L within the ﬁrst week after birth were recruited into the
hyperbilirubinemia group. Control subjects were newborns without
signiﬁcant hyperbilirubinemia (TSB levels b250 μmol/L). Newborns
who exhibited the following criteria were excluded from the study:
prolonged hyperbilirubinemia, hemolysis, polycythemia, birth trauma,
diabeticmother, ABO or Rh incompatibility, glucose-6-phosphate dehy-
drogenase (G6PD) deﬁciency, sepsis, asphyxia, congenital pneumonia,
infection, gross congenital malformations and other medical conditions
that could lead to neonatal hyperbilirubinemia.
2.2. Genomic DNA extraction and genotyping
Buccal swab, a non-invasive and cost-effective sampling tool was
used to collect genomic DNA from the newborns. Brieﬂy, two sterile
buccal swabs were twirled gently on the inside of both cheeks for
about 30 s. Genomic DNA was isolated using Exgene™ Blood SV miniTable 1
HRM primer pairs for genotyping NR1I3 variants.
rs number SNP ID
(Reference)
rs10157822 MPJ6_1I3008 (Ikeda et al., 2003)
rs4073054 IVS8+116TNG (Chew et al., 2013)
rs2307424 540ANG (Ikeda et al., 2003; Chew et al., 2013)
F: forward; R: reverse.kit (GeneAll, Korea) according to the manufacturer's protocol. The
extracted genomic DNA was stored at−20 °C prior to genotyping.
The NR1I3 nucleotide sequence was obtained from the National
Center for Biotechnology Information (NCBI) (accession number:
NG_029113.1). To genotypeMPJ6_1I3008 (rs10157822), IVS8+116TNG
(rs4073054) and 540ANG (rs2307424) single nucleotide polymor-
phisms (SNPs), high resolution melting (HRM) analysis was employed
by using the PikoReal 96 real-timepolymerase chain reaction (PCR) sys-
tem (Thermo Fisher Scientiﬁc Inc., United States). The technique com-
bined real-time PCR and post-PCR HRM in a single experiment. Primer
pairs (Table 1) were designed with the aid of Primer3 web version
4.0.0 (Rozen and Skaletsky, 2000) and analyzed using PCR Primer
Stats (Stothard, 2000) and NCBI BLAST (Altschul et al., 1990). Small
amplicons (99–114 base pairs) were critical to increase the sensitivity
of the HRM assays and to avoid multiple melting domains that would
complicate the interpretation of the results.
The HRM assay required only a single preparation. Brieﬂy, the HRM
assay for each SNP was carried out in 10 μL of ﬁnal volume in a 96-well
Piko PCR white plate (Thermo Fisher Scientiﬁc Inc., United States): 5 μL
of 2× Precision Melt Supermix (Bio-Rad Laboratories, Inc., CA) was
added to 0.2 μL of each forward and reverse primer (10 μM; Sigma-
Aldrich, Malaysia), 1 μL of DNA template (1 ng/μL) and 3.6 μL of distilled
water.
The real-time PCR condition consisted of an initial denaturation step
at 95 °C for 2 min that was followed by 40 cycles of denaturation (95 °C
for 10 s), annealing (58 °C for 30 s) and extension (72 °C for 30 s). The
annealing temperature (Ta) was optimized by gradually increasing or
decreasing the Ta from 54 to 60 °C until an optimal HRM melt proﬁle
was obtained. Although the same Ta was used for all three primer
pairs, HRM assay for each SNP was conducted separately to produce
simple melt proﬁles that facilitated easy interpretation. The subsequent
HRM program comprised heteroduplex formation (denaturation at
95 °C for 30 s and renaturation at 60 °C for 1 min) and high resolution
melt with continuous ﬂuorescence readings from 60 to 95 °C in 0.2 °C
increments.
HRM data was analyzed by the PikoReal Software version 2.1
(Thermo Fisher Scientiﬁc Inc., United States). Genotypes of the samples
were assigned by comparing the melting patterns with that of known
standards. Samples constituting the same nucleotide sequence would
demonstrate a similar melting pattern in the graphs. Hence, three
different melting patterns were produced and that implied the three
genotypes of a SNP.2.3. DNA sequencing
To conﬁrm the validity and reliability of the HRM genotyping results
as well as to assign a genotype for each HRM pattern, representative
samples demonstrating different melting patterns, random samples
and those which generated unusual or ambiguous HRM results were
subjected to DNA sequencing. A commercial kit (GeneAll® Expin™
ComboGP, Korea)was used to purify these samples prior to sequencing.
The sequencing electropherograms were viewed by using Finch TV
version 1.4.0 (Geospiza Inc., Seattle, WA, USA) and compared with thePrimer sequence
(5′ to 3′)
Amplicon size (bp)
F: TGCAGCAGATTCCACTCTCC
R: GGGAACAGACTGCTTTGAGT
99
F: GGTGAAACATTGAGCTTGGG
R: GCTGAAACGATGTGAGACAGG
114
F: CCTGAAAGATGAGGGGAGGT
R: TGGTCACACACTTCGCAGA
106
200 T.P. Cheung et al. / Gene 573 (2015) 198–204NR1I3 sequence from NCBI to derive the genotype for each sequenced
sample.
2.4. Statistical analysis
Statistical analysis was conducted by using IBM® SPSS statistics ver-
sion 20 (SPSS, Chicago, IL, USA) and Epi Info 7 (Dean et al., 2011). To de-
termine the signiﬁcance of difference between the hyperbilirubinemia
and control groups for the baseline demographic data and the frequen-
cies of genotype and allele, Pearson's chi-square test was employed for
categorical variables while independent t test was used to analyze
numerical variables. The association between variant genotypes and
risk of developing neonatal hyperbilirubinemia was explored by using
binary logistic regression analysis with wild-type genotype served as
the reference (odd ratio (OR) of 1.00). p value b0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Characteristics of study subjects
A total of 509 newborns were enrolled in this study, comprising 232
hyperbilirubinemia subjectswith TSB ≥250 μmol/L and 277 control sub-
jects with TSB b250 μmol/L. The baseline demographic and clinical data
were compared between the two subject groups. None of the newborn
in either group had demonstrated any clinical condition that is critical
for the development of neonatal hyperbilirubinemia. We did not
ﬁnd any signiﬁcant difference in the gender, mode of delivery and
birth weight between hyperbilirubinemia and control subjects. On
average, the peak TSB level was observed on day four of life of the
hyperbilirubinemia newborns. In these patients, their peak TSB levelsMPJ6_
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Fig. 1. Segments of the DNA sequence electropherograms to characterize and conﬁrm the geno
heterozygotes. Genotypes are labeled above the electropherograms. Arrows indicate nucleotidwere in the range of 250–324 μmol/L in 144 (62.1%) newborns and 81
(34.9%) newborns were between 325 and 399 μmol/L. Seven (3.0%)
out of 232 hyperbilirubinemia newborns developed peak TSB ≥400
μmol/L which necessitated exchange transfusion.
3.2. NR1I3 variant analysis
A 100% concordance rate was achieved for the genotyping results
produced by HRM and DNA sequencing analysis (data not shown).
DNA sequencing electropherograms (Fig. 1) veriﬁed the nucleotide
changes that were demonstrated by the characteristic HRM melting
patterns. As shown in Figs. 2 and 3, distinctive HRM melting patterns
were produced from different genotypes. DNA samples with identical
nucleotide sequencewere clustered into the same groups and exhibited
similar melting patterns. Contrary, difference in the nucleotide was dis-
tinguished by melting temperature shift and changes in the melting
curve shape. MPJ6_1I3008 (GNA) and 540ANG which involved adenine
(A) and guanine (G) base variation generated similar melting patterns
(Fig. 3). However, the melting temperature of the samples with compa-
rable genotypes (for an example, GA of MPJ6_1I3008 versus AG of
540ANG) was not identical due to different base compositions and
lengths of the amplicons.
The frequencies of genotypes and alleles of MPJ6_1I3008,
IVS8+116TNG and 540ANG were compared between the
hyperbilirubinemia and control groups. The distributions of all variant
genotypes and alleles between the groups were not signiﬁcantly differ-
ent (p N 0.05). The risk of developing neonatal hyperbilirubinemia for
each NR1I3 variant genotype was estimated by logistic regression
analysis (data not shown). The heterozygous and homozygous variant
genotypes of all variants were positively associated with the neonatal
hyperbilirubinemia risk (OR N 1.00), although the associations wereT>G 540A
AA
AG
GG
>G
type for each HRMmelting pattern. Two peaks were observed in the electropherograms of
e changes.
IVS8
A 
C 
+116T>G
B
D
Fig. 2.HRMmelt proﬁles for discriminating the genotypes of IVS8+116TNG. Fluorescence signals of the (A) normalizedmelt curvewere normalized to relative values of 100 and 0. Unique
melting patterns for each genotype were observed in the (B) normalized and temperature shifted derivative HRM graph, (C) normalized RFU difference graph and (D) normalized
and temperature shifted difference graph [the sample curves were subtracted from the standards (knownwild type, heterozygote and homozygous variant) to magnify small differences
between each melt curve cluster]. Genotype of each melting pattern was assigned after conﬁrmed with DNA sequencing. RFU, relative ﬂuorescence units.
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zygous and homozygous variant genotypes for each variant were also
similar.
The results obtained were also stratiﬁed by gender (Table 2).
The heterozygous genotypes of MPJ6_1I3008 in both genders were
associated with a reduced neonatal hyperbilirubinemia risk, although
the associationswere not statistically signiﬁcant. Thesewere not similar
to the overall risk association of MPJ6_1I3008 which demonstrated an
elevated risk. Likewise, no statistically signiﬁcant risk association was
found for the homozygous variant genotype in males (OR, 1.06;
95% CI, 0.55–2.01; p=0.870). Stratiﬁcation by gender revealed a signif-
icant inverse association between homozygous variant genotype of
MPJ6_1I3008 and risk of neonatal hyperbilirubinemia in the female
newborns (OR, 0.44; 95% CI, 0.20–0.95; p= 0.034).
For IVS8+116TNG,we did notﬁndany signiﬁcant risk association for
the heterozygous genotype in both genders, and the homozygous vari-
ant genotype inmales. Although the homozygous variant genotypewas
not present in the female hyperbilirubinemia newborns, a reduced
number (less than ﬁve) of the genotype was found in males and female
controls. Stratiﬁcation analysis of the 540ANG also revealed that in both
genders, the association between neonatal hyperbilirubinemia risk and
variant genotypes was not statistically signiﬁcant.
4. Discussion
The development of neonatal jaundice is multifactorial which in-
volves genetic and environmental components (American Academy of
Pediatrics Subcommittee on Hyperbilirubinemia, 2004; Bhutani et al.,
2004). To date, review of the literature revealed no studieswhich deter-
mine the association between variants in the NR1I3 gene and neonatal
hyperbilirubinemia. In Malay newborns, we did not ﬁnd any signiﬁcantdifference in genotypic distribution ofMPJ6_1I3008, IVS8+116TNG and
540ANG between hyperbilirubinemia and control newborns. However,
we found a signiﬁcant inverse association between female newborns
with homozygous variant genotype ofMPJ6_1I3008 and risk of neonatal
hyperbilirubinemia when gender-based stratiﬁcation analysis was per-
formed. The results suggest the protective role of homozygous variant
genotype against neonatal hyperbilirubinemia in the female Malays.
To the best of our knowledge, comprehensive scanning of the NR1I3
variants was only conducted among the Japanese individuals adminis-
trating drugs (Ikeda et al., 2003) and healthy Singapore Asians (Chew
et al., 2013). The Japanese study identiﬁed a total of 29 SNPs including
three SNPs that were reported previously (Ikeda et al., 2003). Among
all the SNPs, 16 (includingMPJ6_1I3008)were located in the 5′-ﬂanking
region, three in exons and ten in introns. Another study conducted on
healthy Singapore Asians revealed a total of 38 SNPs and 13 out of
which were novel ones (13 SNPs in 5′-ﬂanking region, one in exon
and 24 in introns) (Chew et al., 2013). The variant allele frequency of
MPJ6_1I3008 in our population (43.3% and 47.3% in patients and con-
trols respectively) was lower than the Japanese (66.4%) (Ikeda et al.,
2003). This 5′-ﬂanking SNPmay have an effect on the promoter regula-
tory activity but the exact mechanism remains to be clariﬁed. Variation
in the distribution between the Malays and Japanese highlights the
possible inﬂuence of ethnicity and background of subjects on genetic
variation.
A study from Singapore showed that the homozygous variant geno-
type of IVS8+116TNG was not detected in 54 healthy Malay subjects
and the variant allele frequency was 8.3% (Chew et al., 2013). However,
both the heterozygous and homozygous variant genotypes were pres-
ent in our subjects with a higher frequency (16.4%). The exonic SNP
540ANG (Pro180Pro) was mapped to the ligand binding domain of
NR1I3 (di Masi et al., 2009). In-silico analysis showed that the silent
M54
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Fig. 3.HRMmelting patterns generated fromMPJ6_1I3008 (i and ii) and 540ANG (iii and iv)were almost similar. Both SNPs involved changes inA andG bases. Therewas a slight difference
in the melting pattern of AA genotype between the SNPs.
Table 2
Stratiﬁcation of neonatal hyperbilirubinemia risk association of NR1I3 variants by gender.
Patients Controls Odd ratio (95% CI) p value
MPJ6_1I3008
Males (n) 133 136
Wild type (GG) 43 (32.3) 44 (32.4) 1.00 (reference) –
Heterozygous (GA) 57 (42.9) 60 (44.1) 0.97 (0.56–1.69) 0.920
Homozygous variant (AA) 33 (24.8) 32 (23.5) 1.06 (0.55–2.01) 0.870
Females (n) 99 141
Wild type (GG) 35 (35.4) 37 (26.2) 1.00 (reference) –
Heterozygous (GA) 50 (50.5) 70 (49.6) 0.76 (0.42–1.36) 0.348
Homozygous variant (AA) 14 (14.1) 34 (24.1) 0.44 (0.20–0.95) 0.034a
IVS8+116TNG
Males (n) 133 136
Wild type (TT) 93 (69.9) 91 (66.9) 1.00 (reference) –
Heterozygous (TG) 36 (27.1) 41 (30.1) 0.86 (0.50–1.46) 0.576
Homozygous variant (GG) 4 (3.0) 4 (2.9) 0.98 (0.24–4.03) 0.976
Females (n) 99 141
Wild type (TT) 80 (80.8) 104 (73.8) 1.00 (reference) –
Heterozygous (TG) 19 (19.2) 32 (22.7) 0.77 (0.41–1.46) 0.426
Homozygous variant (GG) 0 (0.0) 5 (3.5) NA 0.052
540ANG
Males (n) 133 136
Wild type (AA) 35 (26.3) 43 (31.6) 1.00 (reference) –
Heterozygous (AG) 63 (47.4) 58 (42.6) 1.33 (0.75–2.36) 0.322
Homozygous variant (GG) 35 (26.3) 35 (25.7) 1.23 (0.64–2.35) 0.533
Females (n) 99 141
Wild type (AA) 24 (24.2) 37 (26.2) 1.00 (reference) –
Heterozygous (AG) 58 (58.6) 71 (50.4) 1.26 (0.68–2.34) 0.465
Homozygous variant (GG) 17 (17.2) 33 (23.4) 0.79 (0.36–1.73) 0.562
Figures in parenthesis are percentage or 95% CI as applicable.
a Statistically signiﬁcant.
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factor (SRp55) binding (Chew et al., 2013). The variant allele frequency
of the SNP in our study (47.8%) was comparable to those of the healthy
Singapore Malays (45.3%) (Chew et al., 2013). Although the Malay
populations from Singapore and Malaysia may share similar genetic
composition, discrepancy in the frequenciesmay still exist due to differ-
ent characteristics of the subjects, geographical factors and sample size.
A higher incidence of neonatal hyperbilirubinemia in the Asians
compared with the Caucasians suggests that genetic factors could be
the underlying cause for the disease occurrence (Huang et al., 2004;
Morioka et al., 2010). Genetic factors that predispose to neonatal
hyperbilirubinemia including the UGT1A1, G6PD and SLCO1B1 variants
have been extensively explored in various ethnicities (Watchko and
Lin, 2010; Yusoff et al., 2010; Liu et al., 2013; D'Silva et al., 2014;
Tiwari et al., 2014). Generally, these variants contribute to neonatal
hyperbilirubinemia by disrupting the balance between bilirubin
production and elimination (Kaplan et al., 2002). However, no studies
have targeted the NR1I3 gene yet.
Since the protein product of NR1I3, CAR, regulates the bilirubin
excretion by inducing important components (SLCO1B1, GSTA1,
GSTA2, UGT1A1 and MRP2) involved in bilirubin clearance, and the
ability of CAR to stimulate an enhanced bilirubin elimination in re-
sponse to hyperbilirubinemia (Huang et al., 2003), therefore, it is possi-
ble that NR1I3 genetic variants which encode receptors with decreased
amount or functions may affect the occurrence and severity of neonatal
hyperbilirubinemia. The resultingCARmaydemonstrate variable induc-
tion or stimulatory activities on the related components. Additionally,
the regulation of UGT1A1 transcription by CAR which binds to the
gtPBREM (Sugatani et al., 2001) also suggests that any abnormality in
CAR due to the NR1I3 variants may modulate the binding efﬁciency
and lead to a decreased production of UGT1A1 enzyme. Thus, the vari-
ants may indirectly reduce the metabolism of bilirubin and lead to neo-
natal hyperbilirubinemia. However, our ﬁndings demonstrated that
female neonates with homozygous variant genotype of MPJ6_1I3008
have a lower risk of hyperbilirubinemia.
Extensive literature search shows that no studies have provided the-
oretical or functional explanation regarding the genetic mechanism of
the protective role conferred by homozygous variant MPJ6_1I3008
against neonatal hyperbilirubinemia or other diseases. However, some
other mutations demonstrate protective effects in which individuals
with homozygous mutations are protected whereas heterozygous indi-
viduals may have delayed disease progression. For instances, hemoglo-
binopathies (homozygous hemoglobin C and hemoglobin E, sickle-cell
trait and beta thalassemia trait) protect against malaria in endemic re-
gions (Ayi et al., 2004; Williams et al., 2005); heterozygous von Hippel
Lindau (VHLR200W) protects against anemia (Miasnikova et al., 2011);
and homozygous CCR5Δ32 (a 32-bpdeletion in the host-cell chemokine
receptor CCR5) protects against HIV infection (Sullivan et al., 2001).
Since each mutation has different mechanisms in protecting against
disease, further studies are thus required to elucidate the genetic
mechanism of the NR1I3 variants (MPJ6_1I3008, IVS8+116TNG and
540ANG).
Other risk factors that are also associated with neonatal
hyperbilirubinemia comprise hemolysis, cephalohematoma, exclusive
breastfeeding, infant of diabetic mother, East Asian ethnicity and
male gender (American Academy of Pediatrics Subcommittee on
Hyperbilirubinemia, 2004; Maisels et al., 2009; Muchowski, 2014). In
our study, we have excluded subjects who demonstrated potential
medical conditions that were related to hyperbilirubinemia because
these conditions could lead to and affect the severity of the disease.
According to the clinical practice guideline by the American Academy of
Pediatrics, male gender has been assigned as one of the risk factors
(American Academy of Pediatrics Subcommittee on Hyperbilirubinemia,
2004) based on a study in Northern California which found a strong pos-
itive association betweenmale gender and hyperbilirubinemia (OR, 1.95;
p = 0.007) (Newman et al., 2000). However, ﬁndings from our studyshowed that the male gender was not a signiﬁcant predictor of neonatal
hyperbilirubinemia in the Malay subjects.
In this study, the use of HRM analysis has facilitated a sensitive and
rapid genotyping of the NR1I3 variants. Further, the analysis is also rel-
atively inexpensive and straightforward than traditional genotyping
techniques by requiring single preparation and allowing easy interpre-
tation of genotyping results. The non-invasive nature of buccal swab
sampling is more suitable for newborns comparedwith blood sampling
while able to raise participation rate considerably. Our study has
demonstrated that HRM genotyping of DNA material derived from
buccal swab yielded satisfactory and reliable results. A study which
also employed buccal swab sampling indicated that buccal epithelial
cells provided a reliable source of DNA and promising results were ob-
tained from genetic analysis such as short tandem repeat analysis,
Taqman allelic discrimination assay, PCR-restriction fragment length
polymorphism (PCR-RFLP) and whole exome sequencing (Said et al.,
2014).
It is important to note that the analysis of genetic variants responsi-
ble for neonatal hyperbilirubinemia should be as extensive as possible
and incorporate various genes (Watchko et al., 2009). Therefore, addi-
tional genetic variants including those that are involved in the bilirubin
metabolism should also be analyzed to inspect the linkage among them.
Variants in the NR1I3 gene were only studied thoroughly among popu-
lations in Japan and Singapore (Ikeda et al., 2003; Chew et al., 2013).
Findings from these studies can then be employed to further explore
the contribution of different NR1I3 variants on the development of
neonatal hyperbilirubinemia.
5. Conclusion
In conclusion, our results suggested a female-speciﬁc signiﬁcant in-
verse association of the homozygous variant genotype of MPJ6_1I3008
with the risk of neonatal hyperbilirubinemia. Besides, MPJ6_1I3008,
IVS8+116TNG and 540ANG were not signiﬁcantly associated with the
neonatal hyperbilirubinemia risk when compared between the groups
in Malay population.
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